Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$57.26M+2,504%
ALN
Alnylam PharmaceuticalsALNY
$15.71M-65.9%
Zymeworks logo
ZymeworksZYME
$178.79M+13,486%
Amgen logo
AmgenAMGN
——
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
BioCryst Pharmaceuticals (BCRX) reported cash provided by (used in) financing activity, including discontinued operation of $412.55M in Q1 2026.
How has BioCryst Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
BioCryst Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation increased by 77887.1% year-over-year, from $529K to $412.55M.
What is the long-term trend for BioCryst Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation has grown at a -0.9% compound annual growth rate (CAGR), from $359.67M to -$349.93M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.